Micardis®. Observational Study in Patients With Essential Hypertension
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Low dose of Telmisartan, once dailyDrug: High dose of Telmisartan, once daily
- Registration Number
- NCT02200094
- Lead Sponsor
- Boehringer Ingelheim
- Brief Summary
This study is designed to supplement, under conditions of usual clinical practice, the data on the efficacy and safety of Micardis® collected during the clinical studies.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 4532
Inclusion Criteria
- Patients of either sex over the age of 18 years suffering from essential hypertension requiring treatment according to the physician
Exclusion Criteria
- Hypersensitivity to the active component or to any of the excipients
- Pregnancy and lactation
- Biliary obstructive disorders
- Severe hepatic impairment
- Severe renal impairment
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Outpatients with essential hypertension Low dose of Telmisartan, once daily - Outpatients with essential hypertension High dose of Telmisartan, once daily -
- Primary Outcome Measures
Name Time Method Changes in systolic and diastolic blood pressure Baseline, 4 weeks and 3 months after start of treatment Percentage of patients with dose titration to 80 mg 4 weeks and 3 months after start of treatment Number of patients with adverse events Up to 3 months after start of treatment Global evaluation of treatment compliance by investigator, a 6-point rating scale 4 weeks and 3 months after start of treatment
- Secondary Outcome Measures
Name Time Method